Navigation Links
Kensey Nash Reports Third Quarter and First Nine Month Fiscal Year 2009 Results
Date:4/22/2009

lion pre-tax) for the acceleration of stock awards and discontinuation of the Company's embolic protection platform.

In the nine-month period ended March 31, 2009, the total tax-effected impact on earnings per share of equity compensation expense was $0.06, a decrease from $0.25 in the prior year comparable period as a result of the fiscal 2008 acceleration of stock awards triggered by a third party's significant open market purchase of the Company's Common Stock, as well as favorable mark-to-market adjustments on outstanding Stock Appreciation Rights in the current nine-month period, offset in small part by the inclusion in equity compensation expense for the fiscal 2009 period of amortization for an additional year of equity grants caused by the fiscal 2008 acceleration of equity awards.

During the nine-month period, the Company generated cash from operations of $22.0 million and had $75.5 million of cash and investment balances and total debt of $33.1 million at March 31, 2009.

Supplemental Sales Data. Net sales for the third quarter of fiscal 2009 decreased to $13.9 million from $14.1 million in the third quarter of fiscal 2008. Net sales for the first nine months of fiscal 2009 increased to $41.3 million up from $38.8 million in the prior fiscal year period. Additional details are summarized below.

                     Three Months              Nine Months
                       Ended       Year over     Ended        Year over
                      March 31,     Year %      March 31,       Year %
    ($millions)    2009     2008    Change    2009     2008     Change

    Orthopaedic
     Products      $7.7     $7.7      0%     $22.8     $21.1      8%
    Cardiovascular
     Products      $4.6     $4.3      6%     $13.8     $11.7     18%
    Endovascular
     Products      $0.9     $1.6    (39%)     $2.6      $4.6    (43%)
    Other
     Products      $0.7     $0
'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Kensey Nash Corporation Announces Its Third Quarter 2009 Earnings Release Date and Teleconference
2. Kensey Nash Announces 600,000 Share Stock Repurchase Program
3. Kensey Nash to Participate in the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum Conference
4. Kensey Nash Announces Appointment of Chief Financial Officer
5. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
6. Kensey Nash Announces Director Resignation
7. Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference
8. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
9. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference
10. Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance
11. Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Christopher Asandra, M.D., Founder and Chief Medical Officer of ... recent decision to issue a warning on testosterone ... are not supported by science, and that the warning ... “The FDA appears to have developed a case of ... “There is not nearly enough evidence to support the ...
(Date:3/4/2015)... TROY Healthcare Solutions will be introducing TROY ... level of security for prescriptions, in Houston, Texas on ... Center located at 6633 Travis Street from 7 AM ... TROY Healthcare Solutions will host a continental breakfast. Starting ... presentations each hour to introduce attendees to TROY Secure ...
(Date:3/4/2015)... 04, 2015 Cook For Your Life ... teaches healthy cooking to people touched by cancer, is ... The program, run by founder Ann Ogden, will be ... Management. The unique partnership will expand the program from ... CFYL in 2007. After going through her own cancer ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Smokers across ... marketing campaign called 'We Love Smokers' from Aqua-Tine, the ... tobacco. , "It’s important to establish a clear ... to it. Our idea, 'We Love Smokers' elevates the ... of view. We created a bold tone of voice ...
(Date:3/4/2015)... Blake’s All Natural Foods , ... attend this year’s Natural Products Expo West in Anaheim, ... this new line, Blake’s, who has the top four ... its commitment to creating high-quality dishes that are easily ... the natural channel, Blake’s understands what educated consumers are ...
Breaking Medicine News(10 mins):Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 2Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 3
... some students experience while taking their exams may also affect ... allergy// , scientists say. ,Mats Lekander and other ... medical exam affects stress hormone levels, the immune system and ... ,The extensive tests were conducted on two occasions - first ...
... death toll from the ‘Typhoon Saomai’ has risen to 330. ... had increased// after 6 more bodies were discovered in the ... bodies were fished out from the sea, off the Shacheng ... 186. ,Cai Meisheng, vice mayor of Fuding, said ...
... eyesight, but according to a recent research, yellow and green vegetables ... be good for the eyesight. ,The diets of 1,700 American ... researchers at the University of Wisconsin to observe the affect of ... carried out by asking each woman what was her regular diet ...
... that getting married may benefit depressed people more than it ... beneficial to the general well being of a person, but ... health aspect of tying the knot. ,“Our findings question ... for all individuals,” observed co-author Adrianne Frech, a doctoral student ...
... child attending the Craigneuk Nursery Centre in Wishaw is recovering at ... O157 infection. ,The Craigneuk Nursery Centre cares for ... ,A NHS Lanarkshire, spokesman who refused to reveal ... children had been contacted as a precaution. ,A ...
... has touched the 25 year mark and this year ... With increasing// access to lifesaving treatments last year even ... reported declining HIV infection rates. However Bill Gates addressing ... that current trends don’t bode well for the future ...
Cached Medicine News:Health News:Yellow and green vegetables for better eyesight 2Health News:Need for Change in Social Norms to Prevent Spread of HIV 2Health News:Need for Change in Social Norms to Prevent Spread of HIV 3
(Date:3/4/2015)... Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), ... today announced its financial results for the fourth quarter ... 2014 Financial Highlights , Total sales in ... 36.8% excluding the impact of foreign currency exchange rate ... same quarter of 2013. , Gross profit increased ...
(Date:3/4/2015)... Mass., March 4, 2015 GSI Group Inc. ... "GSI"),  a global leader and supplier of precision photonics ... equipment and advanced industrial technology markets, today reported financial ... Unless otherwise noted, all financial results in this press ... Fourth QuarterDuring the fourth quarter of 2014, GSI ...
(Date:3/4/2015)... -- Alimera Sciences, Inc. (NASDAQ: ALIM ... the research, development and commercialization of prescription ophthalmic ... quarter and year ended December 31, 2014. ... for Alimera Sciences, most notably having received U.S. ... treatment of diabetic macular edema," said Dan Myers, ...
Breaking Medicine Technology:China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 10GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 11GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 12GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 13GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 14GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 15
... of Disease Activity as Measured,by MRI and Relapse ... May 1, 2007 -- Genentech, Inc.,(NYSE: DNA) ... from a Phase II clinical study of Rituxan®,(rituximab) in ... the American Academy of Neurology,annual meeting held in Boston. ...
... BOSTON--(BUSINESS WIRE)--May 1, 2007 - Significantly more patients,treated ... percent or,more compared with placebo, according to study ... annual meeting.,Clinically, this outcome would equate to a ... to moderate pain., Fibromyalgia is one of the ...
Cached Medicine Technology:Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6Lyrica Significantly Reduced Pain and Helped Patients Manage the,Symptoms of Fibromyalgia, Data Show 2Lyrica Significantly Reduced Pain and Helped Patients Manage the,Symptoms of Fibromyalgia, Data Show 3
... best lens available for ... One 62 mirror. Tilted ... and laser beam astigmatism. ... used on most patients ...
Direct gonioscopy lens with magnification. The lens rests on the scleral flange creating a corneal vault and leaving the anterior chamber angle undisturbed. Three sizes available....
Lacrimal cannula blunt tip with 0.3 mm side port, straight....
West lachrymal cannula, blunt tip with inner side opening, gently curved shaft....
Medicine Products: